BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 11244498)

  • 1. Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells.
    Balañá ME; Labriola L; Salatino M; Movsichoff F; Peters G; Charreau EH; Elizalde PV
    Oncogene; 2001 Jan; 20(1):34-47. PubMed ID: 11244498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity.
    Salatino M; Schillaci R; Proietti CJ; Carnevale R; Frahm I; Molinolo AA; Iribarren A; Charreau EH; Elizalde PV
    Oncogene; 2004 Jul; 23(30):5161-74. PubMed ID: 15122317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interactions between progestins and heregulin (HRG) signaling pathways: HRG acts as mediator of progestins proliferative effects in mouse mammary adenocarcinomas.
    Balañá ME; Lupu R; Labriola L; Charreau EH; Elizalde PV
    Oncogene; 1999 Nov; 18(46):6370-9. PubMed ID: 10597237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heregulin induces transcriptional activation of the progesterone receptor by a mechanism that requires functional ErbB-2 and mitogen-activated protein kinase activation in breast cancer cells.
    Labriola L; Salatino M; Proietti CJ; Pecci A; Coso OA; Kornblihtt AR; Charreau EH; Elizalde PV
    Mol Cell Biol; 2003 Feb; 23(3):1095-111. PubMed ID: 12529413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progestins induce transcriptional activation of signal transducer and activator of transcription 3 (Stat3) via a Jak- and Src-dependent mechanism in breast cancer cells.
    Proietti C; Salatino M; Rosemblit C; Carnevale R; Pecci A; Kornblihtt AR; Molinolo AA; Frahm I; Charreau EH; Schillaci R; Elizalde PV
    Mol Cell Biol; 2005 Jun; 25(12):4826-40. PubMed ID: 15923602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Type I insulin-like growth factor receptor antisense strategies in experimental breast cancer].
    Salatino M; Schillaci R; Proietti CJ; Carnevale R; Charreau EH; Elizalde PV
    Medicina (B Aires); 2004; 64(2):129-34. PubMed ID: 15628299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of insulin-like growth factors-I and -II and their receptors in medroxyprogesterone acetate-induced growth of mouse mammary adenocarcinomas.
    Elizalde PV; Lanari C; Molinolo AA; Guerra FK; Balañá ME; Simian M; Iribarren AM; Charreau EH
    J Steroid Biochem Mol Biol; 1998 Nov; 67(4):305-17. PubMed ID: 9883987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924.
    Haluska P; Carboni JM; TenEyck C; Attar RM; Hou X; Yu C; Sagar M; Wong TW; Gottardis MM; Erlichman C
    Mol Cancer Ther; 2008 Sep; 7(9):2589-98. PubMed ID: 18765823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progestin-induced caveolin-1 expression mediates breast cancer cell proliferation.
    Salatino M; Beguelin W; Peters MG; Carnevale R; Proietti CJ; Galigniana MD; Vedoy CG; Schillaci R; Charreau EH; Sogayar MC; Elizalde PV
    Oncogene; 2006 Dec; 25(59):7723-39. PubMed ID: 16799639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of cell growth of a progestin-dependent murine mammary carcinoma in vitro: progesterone receptor involvement in serum or growth factor-induced cell proliferation.
    Lamb C; Simian M; Molinolo A; Pazos P; Lanari C
    J Steroid Biochem Mol Biol; 1999; 70(4-6):133-42. PubMed ID: 10622401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of cell cycle arrest in response to TGF-beta in progestin-dependent and -independent growth of mammary tumors.
    Salatino M; Labriola L; Schillaci R; Charreau EH; Elizalde PV
    Exp Cell Res; 2001 Apr; 265(1):152-66. PubMed ID: 11281653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunization with murine breast cancer cells treated with antisense oligodeoxynucleotides to type I insulin-like growth factor receptor induced an antitumoral effect mediated by a CD8+ response involving Fas/Fas ligand cytotoxic pathway.
    Schillaci R; Salatino M; Cassataro J; Proietti CJ; Giambartolomei GH; Rivas MA; Carnevale RP; Charreau EH; Elizalde PV
    J Immunol; 2006 Mar; 176(6):3426-37. PubMed ID: 16517711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Growth hormones and oncogenes in mammary adenocarcinomas induced by medroxyprogesterone acetate in BALB/c mice].
    Elizalde PV; Balaña ME; Charreau EH
    Medicina (B Aires); 1997; 57 Suppl 2():70-4. PubMed ID: 9580484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor.
    Knowlden JM; Hutcheson IR; Barrow D; Gee JM; Nicholson RI
    Endocrinology; 2005 Nov; 146(11):4609-18. PubMed ID: 16037379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
    Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
    Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin-like growth factor and epidermal growth factor independence in human mammary carcinoma cells with c-erbB-2 gene amplification and progressively elevated levels of tyrosine-phosphorylated p185erbB-2.
    Ram TG; Dilts CA; Dziubinski ML; Pierce LJ; Ethier SP
    Mol Carcinog; 1996 Mar; 15(3):227-38. PubMed ID: 8597535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Five novel hormone-responsive cell lines derived from murine mammary ductal carcinomas: in vivo and in vitro effects of estrogens and progestins.
    Lanari C; Lüthy I; Lamb CA; Fabris V; Pagano E; Helguero LA; Sanjuan N; Merani S; Molinolo AA
    Cancer Res; 2001 Jan; 61(1):293-302. PubMed ID: 11196177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin-like growth factor-1 receptor and ErbB kinase inhibitor combinations block proliferation and induce apoptosis through cyclin D1 reduction and Bax activation.
    Wilsbacher JL; Zhang Q; Tucker LA; Hubbard RD; Sheppard GS; Bamaung NY; Fidanze SD; Wang GT; Hu X; Davidsen SK; Bell RL; Wang J
    J Biol Chem; 2008 Aug; 283(35):23721-30. PubMed ID: 18559346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benzo[a]pyrene- and TCDD-induced alterations in tyrosine phosphorylation and insulin-like growth factor signaling pathways in the MCF-10A human mammary epithelial cell line.
    Tannheimer SL; Ethier SP; Caldwell KK; Burchiel SW
    Carcinogenesis; 1998 Jul; 19(7):1291-7. PubMed ID: 9683191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small interfering RNA targeted to IGF-IR delays tumor growth and induces proinflammatory cytokines in a mouse breast cancer model.
    Durfort T; Tkach M; Meschaninova MI; Rivas MA; Elizalde PV; Venyaminova AG; Schillaci R; François JC
    PLoS One; 2012; 7(1):e29213. PubMed ID: 22235273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.